Clinical Trials Search at Vanderbilt-Ingram Cancer Center
Loncastuximab Tesirine for the Treatment of Relapsed or Refractory Marginal Zone Lymphoma
Lymphoma
Lymphoma
This phase II trial tests whether loncastuximab tesirine works to shrink tumors in patients with marginal zone lymphoma (MZL), a type of immune cell cancer, that has come back (relapsed) or become unresponsive to one or more treatments (refractory). Loncastuximab tesirine is composed of an antibody, called loncastuximab linked to a chemotherapy drug called tesirine. Loncastuximab attaches to specific proteins in the cancer cell and delivers tesirine only to the cancer cells because of this antibody. Ultimately this results in cancer cell death only without exposing normal cells to the tesirine.
Lymphoma
II
Oluwole, Olalekan
NCT05296070
VICC-ITCTT23024
Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Patients with Multiple Myeloma
Multiple Myeloma
Multiple Myeloma
Multiple Myeloma
N/A
Oluwole, Olalekan
NCT05346835
VICC-XDCTT24033
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Multiple Cancer Types
CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity
of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after
lymphodepletion consisting of cyclophosphamide and fludarabine.
of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after
lymphodepletion consisting of cyclophosphamide and fludarabine.
Lymphoma,
Phase I
I
Oluwole, Olalekan
NCT04637763
VICC-DTCTT23155P